Abbott Laboratories: stocks, financial statements

Disable ads for free
Dividends News
Favorites

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

  • ABT Ticker
  • NYSE Exchange
  • 103,000 Employees
13 rated
  • $111.30, +$1.26 (+1.15%) Previous Close
  • 4,480,173 Previous Volume
  • $61.86 / $113.96 52 week low / high
  • -2.33% Percent off 52 week high
  • 2021-01-15 Updated
  • 1.29% Dividend Yield (trailing)
  • 1.62% Dividend Yield (forward)
  • 0 Public float
  • 1,772,361,581 Outstanding shares
  • 58.33 P/E
  • 197.26 B Market Cap
Disable ads for free

Financial statements — Abbott Laboratories

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
32B 31B 27B 21B 20B
Cost Of Revenue
13B 15B 14B 9.6B 9.4B
Gross Profit
19B 16B 13B 11B 11B
Research and Development
2.4B 2.3B 2.1B 1.4B 1.4B
Selling General and Admin
9.8B 9.7B 8.9B 6.6B 6.6B
Operating Expense
25B 27B 25B 18B 17B
Operating Income
4.5B 3.8B 2.1B 3.2B 2.9B
Other Income Expense Net
-460M -970M 95M -1.8B 230M
EBIT
4.5B 3.8B 2.1B 3.2B 2.9B
Interest Income
580M 730M 880M 300M 180M
Pretax Income
4.1B 2.9B 2.2B 1.4B 3.2B
Income Tax
390M 540M 1.9B 350M 580M
Minority Interest
0 0 0 0 0
Net Income
3.7B 2.4B 470M 1.4B 2.7B
Net Income Basic
3.7B 2.4B 470M 1.4B 2.7B
19 ← 15 2019 2018 2017 2016 2015
Current cash
3.9B 3.8B 9.4B 19B 5B
Short term investments
280M 240M 200M 160M 1.1B
Receivables
5.4B 5.2B 5.2B 3.2B 3.4B
Inventory
4.3B 3.8B 3.6B 2.4B 2.6B
Other current assets
1.8B 1.6B 1.7B 2.3B 2B
Current assets
16B 15B 20B 27B 14B
Long term investments
930M 900M 880M 2.9B 4B
Property plant equipment
9B 7.6B 7.6B 5.7B 5.7B
Goodwill
23B 23B 24B 7.7B 9.6B
Intangible assets
17B 19B 21B 4.5B 5.6B
Other assets
2.1B 1.9B 2.1B 3.3B 490M
Total assets
68B 67B 76B 55B 44B
Accounts payable
3.3B 3B 2.4B 1.2B 1.1B
Current long term debt
1.3B 7M 510M 3M 3M
Other current liabilities
5.7B 5.5B 5.5B 4B 4.5B
Total current liabilities
11B 9B 8.9B 6.7B 9.2B
Long term debt
17B 19B 27B 21B 5.9B
Other liabilities
3.4B 4B 4.4B 1.5B 1.2B
Minority Interest
0 0 0 0 0
Total Liabilities
37B 36B 45B 34B 23B
Common stock
1.8B 1.8B 1.7B 1.5B 1.5B
Retained earning
26B 25B 24B 26B 26B
Treasury stock
14M 15M 14M 6M 4.2M
Capital surplus
Shareholder equity
31B 31B 31B 21B 21B
Net tangible assets
-44B -45B -47B -5.6B -9.3B
19 ← 15 2019 2018 2017 2016 2015
Net Income
3.7B 2.4B 470M 1.4B 2.7B
Depreciation
3B 3.3B 3B 1.4B 1.5B
Changes in receivables
-240M 67M -2B 170M
Changes in inventories
-590M -510M 250M -98M -260M
Cash change
16M -5.6B -9.2B 14B 940M
Cash flow
6.1B 6.3B 5.6B 3.2B 3B
Capital expenditures
-1.6B -1.4B -1.1B -1.1B -1.1B
Investments
-82M -58M 2.6B 890M 1.5B
Investing activity other
Total investing cash flows
-1.8B -1.4B -9.6B -250M 410M
Dividends paid
-2.3B -2B -1.8B -1.5B -1.4B
Net borrowings
-1.6B -8.5B -2.9B 13B 1.1B
Other financing cash flows
-13M -200M -17M
Cash flow financing
-4.3B -10B -5.3B 11B -2.2B
Exchange rate effect
-16M -120M 120M -480M -200M
Disable ads for free
Disable ads for free